KRN321
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout KRN321
KRN321 is a phase 2 stage product being developed by Kyowa Kirin for MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT01497145. Target conditions include MDS.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01497145 | Phase 2 | Completed |
Competing Products
20 competing products in MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 25 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| Azacitidine + Venetoclax | AbbVie | Phase 1 | 33 |
| venetoclax + azacitidine | AbbVie | Phase 1 | 33 |
| Venetoclax + Azacitidine + Placebo | AbbVie | Phase 3 | 77 |
| venetoclax + azacitidine +/- donor lymphocyte infusion | AbbVie | Phase 1/2 | 41 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Azacitidine and LDE255 | Novartis | Phase 1 | 33 |
| MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine) | Novartis | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| Azacitidine + Azacitidine plus Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox, Vitamin D and Azacitidine | Novartis | Phase 1/2 | 41 |
| LGH447 + LGH447 + midostaurin | Novartis | Phase 1 | 33 |
| Panobinostat | Novartis | Phase 1 | 33 |
| sabatolimab + azacitidine + venetoclax | Novartis | Phase 2 | 52 |
| LBH589 + Epoetin Alfa | Novartis | Phase 2 | 52 |
| Placebo + Romiplostim | Amgen | Phase 2 | 51 |
| Darbepoetin alfa + Placebo | Amgen | Phase 3 | 76 |
| Darbepoetin Alfa | Amgen | Phase 3 | 76 |